Head and Neck Cancer Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Condition: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Pembrolizumab; Drug: IO102-103 Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; IO Biotech; Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 7, 2023 Category: Research Source Type: clinical trials
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
Conditions: Recurrent Head and Neck Cancer; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Carcinoma; Metastatic Head-and-neck Squamous-cell Carcinoma; Metastatic Head and Neck Cancer; HNSCC Interventions: Drug: Ramucirumab; Drug: Pembrolizumab Sponsors: Washington University School of Medicine; Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 7, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Condition: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Pembrolizumab; Drug: IO102-103 Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; IO Biotech; Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 7, 2023 Category: Research Source Type: clinical trials
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
Conditions: Recurrent Head and Neck Cancer; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Carcinoma; Metastatic Head-and-neck Squamous-cell Carcinoma; Metastatic Head and Neck Cancer; HNSCC Interventions: Drug: Ramucirumab; Drug: Pembrolizumab Sponsors: Washington University School of Medicine; Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 7, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Condition: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Pembrolizumab; Drug: IO102-103 Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; IO Biotech; Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 7, 2023 Category: Research Source Type: clinical trials
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
Conditions: Recurrent Head and Neck Cancer; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Carcinoma; Metastatic Head-and-neck Squamous-cell Carcinoma; Metastatic Head and Neck Cancer; HNSCC Interventions: Drug: Ramucirumab; Drug: Pembrolizumab Sponsors: Washington University School of Medicine; Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 7, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Condition: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Pembrolizumab; Drug: IO102-103 Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; IO Biotech; Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 7, 2023 Category: Research Source Type: clinical trials
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
Conditions: Recurrent Head and Neck Cancer; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Carcinoma; Metastatic Head-and-neck Squamous-cell Carcinoma; Metastatic Head and Neck Cancer; HNSCC Interventions: Drug: Ramucirumab; Drug: Pembrolizumab Sponsors: Washington University School of Medicine; Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 7, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Condition: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Pembrolizumab; Drug: IO102-103 Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; IO Biotech; Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 7, 2023 Category: Research Source Type: clinical trials
